L.E.K. Executive Insights: Raising Orphans and Treating Rare Diseases

So-called "orphan diseases" are rare conditions that affect fewer than 200,000 people per year in the U.S. At a time when pharmaceutical firms are contending with an increasingly challenging industry environment, the orphan sector offers the alluring prospect of strong growth and attractive profit margins--along with the opportunity to improve the lives of patients with often debilitating conditions. However, there are several trends that make being a player in orphan drugs a more challenging proposition than in the past. L.E.K. Managing Director Ian Tzeng looks at the changing dynamics of the orphan drug market and identifies winning strategies designed to capture value within this sector.

See the full Executive Insights here: http://www.lek.com/our-publications/lek-insights/how-pharma-can-capture-value-while-treating-rare-diseases-orphan-drugs 

Connect with L.E.K. Consulting here:

Follow us on LinkedIn:https://www.linkedin.com/company/l.e.k.-consulting
Like us on Facebook: http://www.facebook.com/L.E.K.Consulting
Follow us on Twitter: https://twitter.com/#!/LEK_Consulting

Add new comment